1. Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode.
- Author
-
Down K, Amour A, Anderson NA, Barton N, Campos S, Cannons EP, Clissold C, Convery MA, Coward JJ, Doyle K, Duempelfeld B, Edwards CD, Goldsmith MD, Krause J, Mallett DN, McGonagle GA, Patel VK, Rowedder J, Rowland P, Sharpe A, Sriskantharajah S, Thomas DA, Thomson DW, Uddin S, Hamblin JN, and Hessel EM
- Subjects
- Animals, Crystallography, X-Ray, Female, Male, Mice, Inbred BALB C, Molecular Structure, Phosphoinositide-3 Kinase Inhibitors chemical synthesis, Phosphoinositide-3 Kinase Inhibitors metabolism, Protein Binding, Rats, Wistar, Structure-Activity Relationship, Sulfonamides chemical synthesis, Sulfonamides metabolism, Mice, Rats, Class I Phosphatidylinositol 3-Kinases metabolism, Phosphoinositide-3 Kinase Inhibitors pharmacology, Sulfonamides pharmacology
- Abstract
Optimization of a previously reported lead series of PI3Kδ inhibitors with a novel binding mode led to the identification of a clinical candidate compound 31 (GSK251). Removal of an embedded Ames-positive heteroaromatic amine by reversing a sulfonamide followed by locating an interaction with Trp760 led to a highly selective compound 9 . Further optimization to avoid glutathione trapping, to enhance potency and selectivity, and to optimize an oral pharmacokinetic profile led to the discovery of compound 31 (GSK215) that had a low predicted daily dose (45 mg, b.i.d) and a rat toxicity profile suitable for further development.
- Published
- 2021
- Full Text
- View/download PDF